Pharsight

Fensolvi Kit patents expiration

FENSOLVI KIT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8470359 TOLMAR Sustained release polymer
Oct, 2023

(16 days from now)

Fensolvi Kit is owned by Tolmar.

Fensolvi Kit contains Leuprolide Acetate.

Fensolvi Kit has a total of 1 drug patent out of which 0 drug patents have expired.

Fensolvi Kit was authorised for market use on 01 May, 2020.

Fensolvi Kit is available in powder;subcutaneous dosage forms.

Fensolvi Kit can be used as method of treating pediatric patients 2 years of age and older with central precocious puberty.

The generics of Fensolvi Kit are possible to be released after 15 October, 2023.

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) May 1, 2023

Drugs and Companies using LEUPROLIDE ACETATE ingredient

Market Authorisation Date: 01 May, 2020

Treatment: Method of treating pediatric patients 2 years of age and older with central precocious puberty

Dosage: POWDER;SUBCUTANEOUS

More Information on Dosage

FENSOLVI KIT family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic